Clinical Trials Logo

Head and Neck Cancer Stage III clinical trials

View clinical trials related to Head and Neck Cancer Stage III.

Filter by:
  • None
  • Page 1

NCT ID: NCT05898789 Recruiting - Lymphoma Clinical Trials

Virtual Rehabilitation for Cancer Survivors

Start date: July 7, 2023
Phase: N/A
Study type: Interventional

Pragmatic hybrid type 1 effectiveness-implementation (E-I) trial of a virtual cancer rehabilitation program: The study team will conduct a multi-center hybrid type I effectiveness-implementation study to examine the clinical effectiveness and implementation potential of an 8-week multidimensional virtual cancer rehabilitation intervention (CaRE@Home) for cancer survivors with identified cancer-related impairments on level of overall disability (primary outcome) and patient reported physical and social functioning, anxiety, work status, quality of life, and physiologic changes (secondary outcomes). The study team will conduct a multi-centre pragmatic randomized controlled trial (RCT) (Vancouver, Toronto, Saint John and St. John's) to evaluate effectiveness and using the CIFR, the study team will identify potential factors that may affect successful implementation and integration of CaRE@Home in different cancer settings.

NCT ID: NCT03993353 Recruiting - Cancer Clinical Trials

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.

NCT ID: NCT03795610 Recruiting - Clinical trials for Head and Neck Cancer

Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Start date: March 6, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Patients will be treated with 2 weeks of IPI-549, a specific PI3Kγ inhibitor. Tumor tissue for research purposes through core biopsies will be obtained prior to initiation of IPI-549 and at surgery.